NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 4 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
Q3 2024 vs. Q2 2024
How the institutions holding NewAmsterdam Pharma Co N.V. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 90 | 2 | 100 | +12 |
| Shares | 72.0M | 42.4K | 77.1M | +5.12M (+7.1%) |
| Value | $1.38B | $814.0K | $1.28B | −$102.8M (−7.4%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (22)
Institutions that held NewAmsterdam Pharma Co N.V. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Siren, L.L.C. | 920,564 | $15.3M | 0.76% |
| Rock Springs Capital Management LP | 353,319 | $5.87M | 0.19% |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 287,535 | $4.77M | 0.17% |
| Readystate Asset Management LP | 121,000 | $2.01M | 0.10% |
| Two Sigma Advisers, LP | 97,500 | $1.62M | 0.00% |
| CenterBook Partners LP | 85,695 | $1.42M | 0.09% |
| Alps Advisors Inc | 69,660 | $1.16M | 0.01% |
| BlackRock, Inc. | 66,673 | $1.11M | 0.00% |
| Walleye Capital LLC | 46,947 | $779.3K | 0.01% |
| Lisanti Capital Growth, LLC | 42,165 | $699.9K | 0.18% |
| HRT Financial LP | 37,601 | $624.0K | 0.00% |
| DCF Advisers, LLC | 34,000 | $564.4K | 0.29% |
| Balyasny Asset Management LLC | 21,283 | $353.3K | 0.00% |
| D. E. Shaw & Co., Inc. | 18,345 | $304.5K | 0.00% |
| Squarepoint Ops LLC | 17,133 | $284.4K | 0.00% |
| AQR Capital Management LLC | 15,936 | $264.5K | 0.00% |
| XTX Topco Ltd | 11,265 | $187.0K | 0.01% |
| Tower Research Capital LLC (TRC) | 7,782 | $129.2K | 0.00% |
| Bellevue Group AG | 7,700 | $127.8K | 0.00% |
| Deutsche Bank AG | 2,449 | $40.7K | 0.00% |
| Simplex Trading, LLC | 62 | $1.00K | 0.00% |
| CWM, LLC | 38 | $1.00K | 0.00% |
Sold out (10)
Institutions that held NewAmsterdam Pharma Co N.V. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Artal Group S.A. | 800,000 | $15.4M |
| Superstring Capital Management LP | 64,213 | $1.23M |
| Schonfeld Strategic Advisors LLC | 49,433 | $949.6K |
| J. Goldman & Co LP | 36,776 | $706.5K |
| Vestal Point Capital, LP | 25,000 | $480.3K |
| Acuta Capital Partners, LLC | 22,500 | $432.2K |
| Y-Intercept (Hong Kong) Ltd | 14,607 | $280.6K |
| Parkwood LLC | 13,782 | $265.0K |
| State of Wisconsin Investment Board | 12,171 | $233.8K |
| Banque Cantonale Vaudoise | 2,000 | $38.0K |
Not filed for Q3 2024 yet (2)
Institutions that held NewAmsterdam Pharma Co N.V. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 41,645 | $800.0K |
| Bradley & Co. Private Wealth Management, LLC | 729 | $14.0K |